Literature DB >> 15889380

Decreasing in vitro susceptibility of clinical Staphylococcus aureus isolates to vancomycin at the New York Hospital: quantitative testing redux.

Kyu Y Rhee, David F Gardiner, Macarthur Charles.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15889380     DOI： 10.1086/430175

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  10 in total

1.  In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus.

Authors:  Mao Hagihara; Dora E Wiskirchen; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial.

Authors:  John A Bosso; Jean Nappi; Celeste Rudisill; Marlea Wellein; P Brandon Bookstaver; Jenna Swindler; Patrick D Mauldin
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

3.  Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.

Authors:  R A Keel; P R Tessier; J L Crandon; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

4.  Vancomycin-heteroresistant phenotype in invasive methicillin-resistant Staphylococcus aureus isolates belonging to spa type 041.

Authors:  M Monaco; A Sanchini; H Grundmann; A Pantosti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-04-18       Impact factor: 3.267

5.  Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs.

Authors:  Jason A Crompton; Donald S North; MinJung Yoon; Judith N Steenbergen; Kenneth C Lamp; Graeme N Forrest
Journal:  J Antimicrob Chemother       Date:  2010-06-16       Impact factor: 5.790

6.  Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.

Authors:  Thomas J Dilworth; Jora Sliwinski; Keenan Ryan; Monique Dodd; Renée-Claude Mercier
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

7.  Vancomycin ototoxicity: a reevaluation in an era of increasing doses.

Authors:  Avisheh Forouzesh; Pamela A Moise; George Sakoulas
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

8.  Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy.

Authors:  Abhay Dhand; George Sakoulas
Journal:  F1000 Med Rep       Date:  2012-02-01

9.  Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients.

Authors:  Yun Kim; Soohyun Kim; Jinsook Park; Howard Lee
Journal:  J Pers Med       Date:  2022-01-26

10.  Genotypic and phenotypic relationships among methicillin-resistant Staphylococcus aureus from three multicentre bacteraemia studies.

Authors:  Pamela A Moise; Davida S Smyth; D Ashley Robinson; Nadia El-Fawal; Carlo McCalla; George Sakoulas
Journal:  J Antimicrob Chemother       Date:  2009-03-03       Impact factor: 5.790
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.